MedImmune Collaborates with Johns Hopkins University - - BioPharm International

ADVERTISEMENT

MedImmune Collaborates with Johns Hopkins University


MedImmune, AstraZeneca’s global biologics research and development arm, and The Johns Hopkins University entered into a five-year, $6.5 million research collaboration, according to a joint press release. The joint research projects will focus on MedImmune’s therapeutic areas of interest, including cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; infectious disease; and neuroscience. This new collaboration model extends to both MedImmune’s biologics and AstraZeneca’s small molecule portfolios.  

In oncology, research will explore the role of immune system cells in tumor growth and harness findings to identify new cancer drug targets. In the areas of respiratory, inflammation, and autoimmunity, projects will research the damaging mechanisms underlying rheumatoid arthritis (RA) and validate potential therapeutic targets that may play key roles in the development or progression of RA. In infectious disease, projects will assess monoclonal antibody combinations to aid in clinical candidate selections to more effectively prevent recurrent infections in high-risk patients, such as those with diabetes. This collaboration builds on MedImmune’s ongoing work to prevent serious and costly drug-resistant infections. In antibody discovery and protein engineering, MedImmune will work with the university to find innovative ways to manufacture complex next generation biologic drugs.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Novartis Sells Influenza Vaccine Business to CSL for $275 Million
October 27, 2014
Author Guidelines

Click here